



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Examiner: Robert Clinton HAYES
Frederic J. de SAUVAGE, et al.	)	Art Unit: 1647
Application Serial No. 09/272,835	)	Confirmation No. 6145
Filed: March 19, 1999	)	Attorney's Docket No. 39766-0065 A (P1268R1)
For: <b>GFRα3 AND ITS USES</b>	)	<b>Customer No. 25213</b>

---

EXPRESS MAIL LABEL NO. EL 977 613 021 US  
DATE MAILED: JANUARY 11, 2005

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97**

**MAIL STOP RCE**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450


Sir:

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641, referencing Attorney's Docket No. 39766-0065 A.

Respectfully submitted,


Dated: January 11, 2005

By:   
James A. Fox (Reg. No. 38,455)

**HELLER EHRMAN WHITE & McAULIFFE LLP**

275 Middlefield Road  
Menlo Park, California 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SV 2092138 v1  
1/11/05 2:09 PM (39766.0065)



PTO/SB/08 (2/92)  
Sheet 1 of 1

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>		Attorney's Docket No. <b>39750-0065A</b>		Application Serial No. <b>09/272,835</b>			
(use several sheets if necessary)		Applicant(s) <b>Frederic J. de SAUVAGE, et al.</b>					
		Filing Date: <b>March 19, 1999</b>		Group Art Unit: <b>1647</b>			
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Clas s	Subcla ss	Filing Date (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Clas s	Subcla ss	Translation YES      NO
<b>OTHER DOCUMENTS</b> (including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
	1	Andres et al., <i>Development</i> 128(10):3685-3695 (2001) Multiple effects of artemin on sympathetic neurone generation, survival and growth					
	2	Baloh et al., <i>Neuron</i> 21: 1291-1302 (1998) Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex					
	3	Esteva, "Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer," <i>The Oncologist</i> 9(Suppl 3):4-9 (2004), page 6, column 1, lines 8-16).					
	4	Negro et al., <i>Recent Prog Horm Res.</i> 59:1-12 (2004) Essential roles of Her2/erbB2 in cardiac development and function					
	5	Rosická et al., <i>Physiological Research</i> 51:435-441 (2002) Ghrelin - a New Endogenous Growth Hormone Secretagogue					
	6	Smith et al., <i>Best Pract Res Clin endocrinol Metab.</i> 18(3):333-347 (2004) Growth hormone secretagogues: prospects and potential pitfalls					
	7	Thilenius et al., <i>Eur. J. Immunol.</i> 27(5):1108-1114 (1997) Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants					
EXAMINER:				DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).							